Abstract
RNA electroporated CD40 ligand-activated B cells can induce cytotoxic T-lymphocyte response in vitro. In order to evaluate the effects in vivo, we applied murine spleen B cell vaccine in a mouse model of liver cancer. C57BL/6 mouse spleen B cells were activated by anti-mouse CD40 antibody, recombinant interleukin-4, and cyclosporin A, and then electroporated with total RNA from Hepal-6 cells (Hepal-6 RNA-CD40mAb-B cells). This vaccine was injected into C57BL/6 mice that were subcutaneously inoculated with Hepal-6 cells. Hepal-6 RNA-CD40mAb-B cells could induce tumor-specific cytotoxic T cells and IFN-gamma secretion in the immunized mice. In vivo study showed this vaccine could well inhibit tumor progression, improve overall survival, and provide continuous immunoprotection against Hepal-6 cell-induced tumor. Tumor cell-derived total RNA electroporated B cells vaccine is a type of effective immunotherapy and provides potential implication for clinical treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.